Concordia Names Six Drugs Targeted By UK Competition Inquiry
Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.
You may also be interested in...
The UK’s Competition and Markets Authority has issued a statement of objections to Advanz, Morningside and wholesaler Alliance Healthcare after provisionally finding that the firms broke competition law by arranging to carve up the UK market for nitrofurantoin.
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.